Register entry

Syndax Pharmaceuticals, Inc.

Data as of · How to read this entry

Registered sites
0
Active NDC listings
3
Live patents
9
Exclusivities
1
Countries
0
Catalogue

Drug listings by form and route

3

3 active NDC listings: 3 human prescription drug. By marketing category: NDA 3.

Dosage formNDCs
tablet, film coated3
RouteNDCs
oral3
Labeller name on the listingNDCs
syndax pharmaceuticals, inc.3
Exclusivity

Patents and exclusivities

9
PatentProductCoversExpiry
10683302REVUFORJrevumenib citratesubstance, productJun 2037
11479557REVUFORJrevumenib citrateproductJun 2037
12564590REVUFORJrevumenib citrateproductDec 2042
ProductExclusivityUntil
REVUFORJREVUMENIB CITRATEODE-502 Orphan drugNov 2031
Catalogue

Marketed products

3
BrandGeneric nameForm / routeNDC
Revuforjrevumenibtablet, film coated, oral73555-500NDA
Revuforjrevumenibtablet, film coated, oral73555-501NDA
Revuforjrevumenibtablet, film coated, oral73555-502NDA
Enquiry

Common questions

Is Syndax Pharmaceuticals, Inc. FDA approved?
Syndax Pharmaceuticals, Inc. holds no registered establishment of its own; 3 drug products are listed under its name in the National Drug Code Directory, made at sites registered to other firms.
What drugs does Syndax Pharmaceuticals, Inc. make?
3 products are listed under Syndax Pharmaceuticals, Inc. in the openFDA NDC Directory, most often as tablet, film coated. The full breakdown by dosage form and route is above. A listing count is not a sales figure.

Compiled from FDA establishment registrations, the openFDA NDC Directory, the Orange Book and the FDA drug shortage database. Not claimed by the company. Sources and methodology.